^
    Back
    Association details:
    Biomarker:TBX21 expression
    Cancer:Follicular Lymphoma
    Drug:Opdivo (nivolumab) (PD1 inhibitor) +
    Imbruvica (ibrutinib) (BTK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    EHA 2020
    Title:

    SINGLE-CELL IMMUNE PROFILING PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) B-CELL NON-HODGKIN'S LYMPHOMA (NHL) TREATED WITH IBRUTINIB (IBR) + NIVOLUMAB (NIVO)

    Published date:
    06/12/2020
    Excerpt:
    A large increase in Tbet expression (known to have cytolytic function) at early treatment vs baseline in a CD8+ EM T cell subset was related to longer progression-free survival in FL…